about
Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccinesDo malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?A multidomain adhesion protein family expressed in Plasmodium falciparum is essential for transmission to the mosquitoFunctional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidateUtilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coliApical surface expression of aspartic protease Plasmepsin 4, a potential transmission-blocking target of the plasmodium ookinete.Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.Bacterial superglue enables easy development of efficient virus-like particle based vaccines.Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates.Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in MiceFormulation of vaccines containing CpG oligonucleotides and alumProgress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in miceAnti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgroundsMolecular characterization of the carboxypeptidase B1 of Anopheles stephensi and its evaluation as a target for transmission-blocking vaccines.Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboonsSingle-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervalsAdjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.mosGCTL-7, a C-Type Lectin Protein, Mediates Japanese Encephalitis Virus Infection in Mosquitoes.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, LyonAsymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.
P2860
Q21032495-97E588E4-AE4E-4515-898D-4AFDB712006AQ24805493-F2A08273-2BC7-4648-8624-918ED31FFD16Q27974493-80FFFEED-D174-4AE5-9BA8-613CFF24A248Q28365035-D55DF44F-4036-4821-A744-71097D8BB226Q30243982-7D39CA7E-3187-408C-A10C-7F08F3922377Q33350210-8311748D-DF1D-4D51-B8AD-E22FC1208F58Q33485233-46399E7F-D6B1-4180-81FE-A2E5AF891720Q33707032-26C38C96-B7C8-4F3B-A998-BA88EC5EDD7FQ34341570-0503DF19-3D4A-4576-A429-D16322F65906Q34523734-85DDAB2A-BE5D-4D4B-B296-ADE4CC6ED1E4Q34899015-A6FE5881-E7D1-403E-8D36-153FD283BD81Q35088997-85C2814C-75CD-4A47-B416-7EAD91043B3AQ35138720-BE516295-57CF-41CB-AEFB-DEA1D381A42FQ35575993-E84ECC5B-436A-4665-BB7F-C4B48B5EABBBQ35947113-463F15DE-14B3-497D-AFF6-C8D8A408D5C1Q35998776-0773B8C3-430F-4D85-AC0A-ECC91F1F5D81Q36026296-011B78B8-744D-4D4B-B845-93F68E8B0B26Q36394177-6D04B638-707F-4F03-A5F4-0B6679C5554DQ36611894-47815857-0C12-4C67-9D9A-ADB3D5D7596FQ36670217-7E291EB6-350E-4432-80D5-09C0BFE31280Q36911492-26FE7925-EBBB-47C0-9901-1E8C013BB750Q36911522-EF1A2225-0FC4-4CD9-B78D-992C619D7CB3Q36941152-2B4CDD20-A4AF-4AFF-AFCE-5B782769B5E9Q36998403-4B52DBF6-9444-488A-B418-AD3DB8032196Q37294887-0F0B747C-988D-4650-82BC-9BEE192E86B0Q37587612-EBDB05D9-AB70-49A5-8EC3-D8B4820167B9Q37713285-38951714-AB91-4857-8A20-A8A82F5669B1Q38714302-6FFE0C60-EED5-46EB-B3C2-C1D99B20792AQ40752357-E05E0563-B778-4A00-8C3E-190DE58779B6Q42733080-70CDF866-2BA6-48D1-A92B-CC940B9BBB5EQ52375272-7E2A355D-2787-419B-8A4C-8690BCCDD594
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Transmission-blocking vaccines.
@ast
Transmission-blocking vaccines.
@en
Transmission-blocking vaccines.
@nl
type
label
Transmission-blocking vaccines.
@ast
Transmission-blocking vaccines.
@en
Transmission-blocking vaccines.
@nl
prefLabel
Transmission-blocking vaccines.
@ast
Transmission-blocking vaccines.
@en
Transmission-blocking vaccines.
@nl
P1433
P1476
Transmission-blocking vaccines.
@en
P2093
David C Kaslow
P304
P577
2002-01-01T00:00:00Z